



ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference

February 11, 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 11, 2021-- [ImmunoGen Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming SVB Leerink 10th Annual Global Healthcare Conference. The presentation is scheduled for February 25, 2021 at 3:40pm ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20210211005761/en/>

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.